Evolus (NASDAQ:EOLS) Price Target Raised to $22.00

Evolus (NASDAQ:EOLS) had its target price upped by Barclays from $20.00 to $22.00 in a research note released on Monday morning,Benzinga reports. Barclays currently has an overweight rating on the stock.

A number of other brokerages also recently commented on EOLS. HC Wainwright reissued a “buy” rating and issued a $27.00 price objective on shares of Evolus in a research report on Wednesday, January 22nd. Needham & Company LLC reiterated a “buy” rating and set a $22.00 price target on shares of Evolus in a report on Tuesday, January 21st.

Evolus Trading Up 2.3 %

NASDAQ EOLS opened at $14.56 on Monday. Evolus has a 12 month low of $9.25 and a 12 month high of $17.82. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. The stock has a 50 day moving average of $11.92 and a 200-day moving average of $13.85. The company has a market cap of $921.95 million, a PE ratio of -16.00 and a beta of 1.32.

Hedge Funds Weigh In On Evolus

Large investors have recently modified their holdings of the stock. KBC Group NV acquired a new position in Evolus in the 4th quarter valued at about $49,000. Quarry LP bought a new stake in shares of Evolus during the second quarter worth approximately $54,000. Point72 Asset Management L.P. acquired a new position in shares of Evolus in the third quarter valued at approximately $132,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Evolus during the third quarter worth approximately $191,000. Finally, Profund Advisors LLC acquired a new stake in Evolus during the 2nd quarter worth approximately $130,000. 90.69% of the stock is owned by institutional investors.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.